STOCK TITAN

BIO-TECHNE awards director Higgins 2,750 shares

Nine direct stock-option positions are listed alongside the director's 80,004 directly held common shares.

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

BIO-TECHNE Corp director John L. Higgins received an award of 2,750 shares of common stock on October 29, 2026, at $0 per share. His directly held common-stock position after the award was 80,004 shares. His reported holdings also include nine direct stock-option positions, including options covering 12,500 underlying common shares at an exercise price of $31.26, expiring October 26, 2027.

Insider HIGGINS JOHN L
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 2,750 $0.00 $0.00
Holding Stock Options (Right to Buy) -- -- --
Holding Stock Options (Right to Buy) -- -- --
Holding Stock Options (Right to Buy) -- -- --
Holding Stock Options (Right to Buy) -- -- --
Holding Stock Options (Right to Buy) -- -- --
Holding Stock Options (Right to Buy) -- -- --
Holding Stock Options (Right to Buy) -- -- --
Holding Stock Options (Right to Buy) -- -- --
Holding Stock Options (Right to Buy) -- -- --
Holdings After Transaction: Common Stock — 80,004 shares (Direct); Stock Options (Right to Buy) — 51,381 contracts (Direct)
Awarded common shares 2,750 shares Award dated October 29, 2026
Award price $0 per share Award dated October 29, 2026
Direct common shares after award 80,004 shares Reported after the October 29, 2026 award
Underlying common shares 12,500 shares Direct stock options expiring October 26, 2027
Exercise price $31.26 per share Direct stock options expiring October 26, 2027
Option expiration date October 26, 2027 Direct options covering 12,500 underlying common shares
Stock Options (Right to Buy) technical
"Stock Options (Right to Buy)"
exercise price financial
"exercise price of $31.26"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
underlying shares technical
"underlying shares: 12,500"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BIO-TECHNE (TECH) shares did director John L. Higgins receive?

BIO-TECHNE director John L. Higgins received an award of 2,750 common shares on October 29, 2026, and his directly held common-stock position afterward was 80,004 shares. The listed award price was $0 per share.

What other BIO-TECHNE (TECH) stock options does Higgins hold?

The reported direct options include 7,592 underlying common shares at an exercise price of $44.96, expiring October 25, 2028, and 8,044 shares at $50.41, expiring October 24, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HIGGINS JOHN L

(Last)(First)(Middle)
614 MCKINLEY PLACE NE

(Street)
MINNEAPOLIS MINNESOTA 55413

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/29/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock10/29/2026A2,750A$080,004D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$31.2610/25/201810/26/2027Common Stock12,50012,500D
Stock Options (Right to Buy)$44.9610/24/201910/25/2028Common Stock7,5927,592D
Stock Options (Right to Buy)$50.4110/24/202010/24/2029Common Stock8,0448,044D
Stock Options (Right to Buy)$63.9210/28/202110/29/2030Common Stock6,0286,028D
Stock Options (Right to Buy)$128.8110/27/202210/28/2031Common Stock2,5322,532D
Stock Options (Right to Buy)$73.9410/26/202310/27/2032Common Stock3,4603,460D
Stock Options (Right to Buy)$61.5110/24/202410/26/2033Common Stock3,9373,937D
Stock Options (Right to Buy)$68.3710/24/202510/24/2034Common Stock3,5113,511D
Stock Options (Right to Buy)$60.9610/29/202610/30/2035Common Stock3,7773,777D
Explanation of Responses:
/s/ Andrew Nick as Attorney-in-Fact for John L. Higgins pursuant to Power of Attorney previously filed11/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading